A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies

Diabetes, Obesity and Metabolism

Volumn 19, Issue 3, 2017, Pages 375-386

  Wei, Wenhui ^a   Buysman, Erin ^b   Grabner, Michael ^c   Xie, Lin ^d   Brekke, Lee ^b   Ke, Xuehua ^c   Chu, James W ^e   Levin, Philip A ^f  

^a SANOFI   (France)

^b OPTUM   (United States)

^c HEALTHCORE INC   (United States)

^d STATINMED RESEARCH   (United States)

^e Endocrine and Diabetes Institute   (United States)

^f MODEL Clinical Research   (United States)

Author keywords

basal insulin; database research; incretin therapy; observational study; type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; SCORING SYSTEM; UNITED STATES; WEIGHT CHANGE; CHEMICALLY INDUCED; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; ECONOMICS; FACTUAL DATABASE; GLUCOSE BLOOD LEVEL; HEALTH INSURANCE; HEALTH SERVICE; MEDICATION COMPLIANCE; METABOLISM; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; UTILIZATION;

ADULT; BLOOD GLUCOSE; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN GLARGINE; LIRAGLUTIDE; MALE; MANAGED CARE PROGRAMS; MEDICATION ADHERENCE; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES;

EID: 85010417609     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12828     Document Type: Article

References (59)

1. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care. 2015;38:140-149.
3. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21:438-447.
4. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care. 2005;28:2673-2679.
5. Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33:733-735.
6. Peyrot M, Rubin RR. Physician perception and recommendation of insulin pens for patients with type 2 diabetes mellitus. Curr Med Res Opin. 2008;24:2413-2422.
7. Anderson BJ, Redondo MJ. What can we learn from patient-reported outcomes of insulin pen devices? J Diabetes Sci Technol. 2011;5:1563-1571.
8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
9. Lafeuille MH, Grittner AM, Gravel J, et al. Quality measure attainment in patients with type 2 diabetes mellitus. Am J Manag Care. 2014;20(suppl 1):S5-S15.
10. Quickel KE Jr. Diabetes in a managed care system. Ann Intern Med. 1996;124(1, pt 2):160-163.
11. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12:S101-S108.
12. Lee W, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third party managed care claims data. Clin Ther. 2006;28:1712-1723.
13. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29:1294-1305.
14. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (non-insulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996;81:327-332.
15. Komatsu R, Matsuyama T, Namba M, et al. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7–36)-amide. Diabetes. 1989;38:902-905.
16. Marso SP, Daniels GH, Brown-Frandsen K, et al., LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.
17. Pratley R, Nauck M, Barnett A, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomized, open-label, multicenter, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289-297.
18. Visboll T, Christensen M, Junker A, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: a systematic review and meta-analysis of randomized controlled trials. BMJ. 2012;344:d7771.
19. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerd BJ, Sheri L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22.
20. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3(1):e001986.
21. Cefalu WT, Buse JB, Del Prato S, et al. Beyond metformin: safety consideration in the decision making process for selecting a second medication for type 2 diabetes management. Reflections from a diabetes care editors’ expert forum. Diabetes Care. 2014;37:2647-2659.
22. Faillie JL, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ. 2014;348:g2780.
23. Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014;348:g2366.
24. D'Alessio D, Häring HU, Charbonnel B, et al. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes Obes Metab. 2015;17:170-178.
25. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52:2046-2055.
26. Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox P, Gliklich R. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood). 2010;29:1818-1825.
27. Thayer S, Wei W, Buysman E, et al. The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy. Adv Ther. 2013;30:1128-1140.
28. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted diabetes complications severity index in claims data. Am J Manag Care. 2012;18:721-726.
29. Solberg LI, Engebretson KI, Sperl-Hillen JM, Hroscikoski MC, O'Connor PJ. Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depression. Am J Med Qual. 2006; 21:238-245.
30. Chen G, Khan N, Walker R, Quan H. Validating ICD coding algorithms for diabetes mellitus from administrative data. Diabetes Res Clin Pract. 2010;89:189-195.
31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
32. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139.
33. Ginde AA, Blanc PG, Lieberman RM, Camargo CA Jr. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord. 2008;8:4.
34. NGSP. Harmonizing hemoglobin A1c testing. Convering between IFCC, NGSP and eAG units. http://www.ngsp.org/ifcc.asp. Accessed April 25, 2016.
35. Wei W, Pan C, Xie L, Baser O. Real-world insulin treatment persistence among patients with type 2 diabetes: measures, predictors, and outcomes. Endocr Pract. 2014;20:52-61.
36. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399-424.
37. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
38. Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14:77-82.
39. Fadini GP, Simioni N, Frison V, et al. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. Acta Diabetol. 2013;50:943-949.
40. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843-854.
41. Food and Drug Administration (FDA). Byetta (exenatide) - Renal Failure. 2009. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm. Accessed April 25, 2016.
42. Davies M, Atkin S, Bain SC, et al. Efficacy and safety of liraglutide vs. placebo as add-on to existing diabetes medication in subjects with type 2 diabetes (T2DM) and moderate renal impairment (LIRA-RENAL). Diabetes. 2014;63(suppl. 1):A247-A248 [abstract A965-P].
43. Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia. 2013;56:973-984.
44. Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365:82-93.
45. Westfall JM, Mold J, Fagnan L. Practice-based research--“Blue Highways” on the NIH roadmap. JAMA. 2007;297:403-406.
46. Gandhi GY, Murad MH, Fujiyoshi A, et al. Patient-important outcomes in registered diabetes trials. JAMA. 2008;299:2543-2549.
47. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887-1892.
48. Van Onzenoort HA, Menger FE, Neef C, et al. Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension. 2011;58:573-578.
49. Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122:114-120.
50. Zueger PM, Schultz NM, Lee TA. Cost effectiveness of liraglutide in type II diabetes: a systematic review. Pharmacoeconomics. 2014;32:1079-1091.
51. DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27:309-317.
52. Food and Drug Administration (FDA). FDA approves weight-management drug Saxenda. 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm. Accessed April 25, 2016.
53. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the obesity society. Circulation. 2014;129(suppl 2):S102-S138.
54. Sanofi. 2015. Lantus prescribing information. http://products.sanofi.us/lantus/lantus.html. Accessed April 25, 2016.
55. Sanofi. 2015. Lantus solostar pen guidance. https://www.lantus.com/-/media/ems/conditions/diabetes/brands/lantus/consumer/lantus-solostar-pen-guide.pdf. Accessed April 25, 2016.
56. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442-451.
57. Bonafede MM, Kalsekar A, Pawaskar M, et al. Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis. BMC Endocr Disord. 2011;11:3.
58. Oliveria SA, Menditto LA, Ulcickas Yood M, Koo YH, Wells KE, McCarthy BD. Barriers to the initiation of, and persistence with, insulin therapy. Curr Med Res Opin. 2007;23:3105-3112.
59. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29:682-689.